The Ghent Global IAD Monitoring Tool (GLOBIAD ‐M) to monitor the healing of incontinence‐associated dermatitis (IAD): Design and reliability study
International Wound Journal, EarlyView.
Long-term use of most immunosuppressants to treat allergic contact dermatitis (ACD) generates unavoidable severe side effects, warranting discovery or development of new immunosuppressants with good efficacy a...
Stasis dermatitis (SD) is a common disease in the elderly population, with pruritus being one of the bothersome symptoms. However, there are few therapeutic modalities available for SD-associated itch because little is known about its pathophysiological mechanism. Therefore, we sought to investigate the mediators of itch in SD using an immunofluorescence study on patient lesions focusing on IL-31. Ex vivo stimulation studies using murine peritoneal macrophages were also used to elucidate the pathological mechanisms of IL-31 generation.
For this ‘From the Pages of Allergy Watch’ reviews from several recent issues were selected which review articles about Allergic Skin Diseases, the focus of this issue of the Annals. The first article describes a unique minimally invasive method of skin tape stripping to identify infants with atopic derm atitis who are at increased risk for food allergy. The next study investigates the difference between IgE sensitivity and clinical reactivity to foods in children with atopic dermatitis. The last investigates the impact of UV light exposure and the development of atopic dermatitis in infancy.
The circulating immune phenotype was defined in adults and young children with early atopic dermatitis/AD, but chronologic changes in blood of AD infants and children through adolescence have not been explored.
Atopic dermatitis (AD) is associated with mental health disorders but its impact on global mental health symptoms is less clear.
Atopic dermatitis (AD) is associated with increased systemic inflammation and cardiovascular risk. While previous studies showed increased inflammatory proteins in the blood of AD patients, detailed comparison among AD patients of different ages is unavailable.
Filaggrin is a major epidermal protein that has been shown to be a key player in the pathogenesis of AD and allergic disease. While filaggrin is a significant genetic risk factor for AD, it is also an important disease modifier in AD. Patients with filaggrin related AD and asthma have more frequent hospital admissions and long-term medication costs. Atopic dermatitis patients with FLG mutations are more frequently affected by reduced health related quality of life when compared to AD patients with wild-type FLG.
Disclosures: E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, N...
ConclusionsEvidence on the efficacy and safety of drugs targeting the JAK/STAT pathway for the treatment of patients with AD, vitiligo, or AA is increasing but is still of low quality.
Authors: Maloney NJ, Tegtmeyer K, Zhao J, Worswick S Abstract Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other diseases in dermatology is an area of increasing interest. We searched the literature and ClinicalTrials.gov database for uses of dupilumab beyond atopic dermatitis in dermatology and for ongoing studies on new uses for dupilumab. Off-label reports identified described use of dupilumab for several different dermatologic conditions, including allergic c...